香港, 2025年12月12日 - (亚太商讯 via SeaPRwire.com) - 12月10日，京东工业股份有限公司（「京东工业」或「公司」，股份代号：7618.HK）正式公布全球发售配发结果。公司最终发售价格确定为每股14.10港元，香港公开发售部分反响热烈，实现60.52倍超额认购，共接收超过7万份有效申请，最终发售数目为21,121,000股，占全球发售股份总数的约10%；国际配售部分同样表现亮眼，超额认购倍数约为7.88倍。双重超额认购的市场反馈，充分彰显了全球投资者对京东工业商业模式与发展潜力的高度认可。全链条解决方案铸就领先地位 端到端数智化基础设施赋能庞大客户群作为中国领先的工业供应链技术与服务提供商，京东工业以「太璞」全链路数智化解决方案为核心竞争力，构建起「数」（数智）+「实」（商品）深度融合的服务体系，为企业客户提供覆盖广泛的工业品供应及数智化供应链服务。通过这一体系，公司能够有效满足客户在保供、降本、增效及合规等多维度需求，推动工业供应链领域的数字化变革。凭借深厚的行业积淀，京东工业确立了市场领先地位，已成为中国MRO采购服务市场的最大参与者，根据灼识咨询的数据显示，按2024年的交易额计，公司不仅是中国MRO采购服务市场的龙头企业，规模接近第二名的三倍，同时也是中国工业供应链技术与服务市场的最大服务提供商，市场份额达4.1%，行业标杆地位凸显。这一地位的背后，是京东工业构建的端到端数智化基础设施。基于服务千万企业客户的实战经验，公司打造的「太璞」解决方案，实现了「数」（数智）与「实」（商品）相结合，通过将数智化能力深度赋能客户，引领企业采购供应链的数智化转型。其核心价值在于践行「让数据多跑路，让商品少跑路」的理念，使供需对接更顺畅、匹配更精准、协同更高效，从根本上提升工业供应链的整体韧性与敏捷度。二十余年京东集团供应链管理经验的传承，为京东工业积淀了深厚的专业知识储备。在此基础上，公司不断迭代自身的供应链专业知识，在产品、客户、垂直行业及供货商等领域实现突破，形成了强大的综合竞争力。根据灼识咨询的资料，截至2024年12月31日，公司的SKU数量冠绝中国工业供应链技术与服务市场；截至2025年6月30日，SKU数量已增至约8110万个，2025年6月30日前十二个月内服务重点企业客户约11100个。高客户粘性进一步印证其服务价值，2024年重点企业客户交易额存留率达105.7%，充分体现了客户对其服务的高度信赖与持续认可。收入与盈利高速增长 数字化浪潮助力打开增长空间受益于行业数字化转型浪潮及自身核心能力的持续释放，京东工业近年来业绩实现稳步增长。公司持续经营业务总收入从2022年的人民币（下同）141亿元，增长至2023年的173亿元，2024年进一步攀升至204亿元，复合年增长率达20.1%；从半年期数据看，截至2025年6月30日止六个月，公司持续经营业务总收入达103亿元，较上年同期实现显著增长。同时，公司盈利能力同步实现快速提升，2022年，公司录得经调整净利润7.1亿元，而2024年已大幅攀升至9.1亿元，2025年上半年，公司延续高增长态势，经调整净利润达5.0亿元，较上年同期保持高速增长，展现出强劲的盈利韧性与增长持续性。关于募集资金的用途，京东工业在招股书中已作出明确披露：约35%的募集资金净额计划在未来48至60个月内用于于进一步增强公司的工业供应链能力；约25%的资金净额将投入跨地域业务扩张；约30%的资金净额预留用于潜在战略投资或收购；剩余约10%的资金净额则将用于一般公司用途及补充营运资金，为整体业务的平稳运行筑牢保障。一系列清晰详实的资金规划，既锚定了业务的持续升级与稳健扩张方向，亦彰显出公司强劲的发展活力与健康向好的经营态势。从行业角度来看，中国工业供应链市场的数字化渗透率目前仍处于较低水平，存在巨大的提升空间，根据灼识咨询的数据显示，中国工业供应链市场的数字化渗透率在2024年仅为6.2%，预计到2029年将达到8.2%。数字化渗透率的提高预计将推动工业供应链技术与服务市场规模快速增长，由2024年的人民币0.7万亿元增至2029年的人民币1.1万亿元，复合年增长率达到9.8%，广阔的市场空间为京东工业提供了充足的增长动能。京东工业作为工业供应链数智化转型的领航者，既拥有技术赋能的核心优势，又具备市场领先的规模效应，更手握行业增长的时代机遇。凭借独特的业务模式、覆盖全链路的服务能力及持续迭代的创新实力，在港上市后，公司将持续拓展服务边界与深度，长期增长潜力巨大，有望在实现自身持续成长的同时，为投资者创造长期、稳定的价值回报。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2025年12月12日 - (亚太商讯 via SeaPRwire.com) - 在产业升级、数智化转型加速及政策支持等多重因素驱动下，工业供应链技术正迎来爆发式发展期。作为行业公认的领军企业，京东工业（7618.HK）凭借深厚的技术积淀与全链条服务能力，于12月11日成功登陆港交所，为工业供应链板块注入一枚优质目标，开启发展新征程。数智驱动筑牢壁垒 全链能力构建核心竞争优势作为中国领先的工业供应链技术与服务提供商，京东工业以数智化转型为核心抓手，致力于为客户打造保供、降本、增效及合规的全场景解决方案。公司构建了端到端的供应链数智化基础设施，并通过公司广泛的商品供应、卓越的服务与高效的运营，精准破解工业供应链领域诸多共性痛点，构筑了强大的核心竞争力。基于这套核心基础设施打造的「太璞」解决方案，是京东工业「数」（数智）、「实」（商品）结合的全链路数智化工业供应链的标杆成果，同时，公司采用了轻资产模式搭建高效且可扩展的业务，并通过「太璞」为各行业、各规模的客户提供跨场景、跨品类的全面工业品供应以及技术与服务，真正实现「大小客户全覆盖、全场景需求全满足」。独特的价值创造模式为京东工业积累了广泛且优质的客户基础。根据灼识咨询的数据显示，截至2025年6月30日前的十二个月内，公司服务约11100个重点企业客户。2025年上半年，公司的重点企业客户包括约60%的中国《财富》500强企业及逾40%的在华全球《财富》500强企业，充分印证了市场对其服务能力的高度认可。商品供给能力的广度与深度，是京东工业的另一核心竞争力。根据灼识咨询的数据显示，截至2024年底，按SKU数量计，公司在中国提供最广泛的工业品供应。具体数据方面，截至2025年6月30日，京东工业提供的工业品SKU数量已达约8110万个，全面覆盖80个核心产品类别。截至2025年6月30日前的十二个月内，公司的商品供应源自于由约158000家制造商、分销商及代理商组成的广泛的且覆盖全国的工业品供应网络，彰显强劲综合实力。业绩增长强劲 上市募资锚定长远发展优质的客户结构与高效的运营模式，推动京东工业的业绩实现持续高增长。2022年至2024年，公司持续经营业务总收入从人民币（下同）141亿元稳步增长至204亿元，复合年增长率高达20.1%；盈利能力同步提升，经调整净利润从2022年的7.1亿元大幅攀升至2024年的9.1亿元。2025年上半年，公司延续高增长态势，持续经营业务总收入达103亿元，经调整净利润为5.0亿元，成长韧性凸显。对于本次上市的募集资金用途，京东工业已制定清晰规划：约35%将在未来48至60个月内用于强化核心供应链能力，进一步夯实技术与服务壁垒；约25%将投入跨地域业务扩张，拓展市场覆盖边界；约30%预留用于潜在战略投资或收购，加速生态整合；剩余约10%则用于补充营运资金及一般公司用途。这套「强核心、扩边界、筑生态」的资金规划，为公司长远健康发展提供了坚实保障。综合来看，京东工业凭借数智化技术优势、全链路服务能力、广泛的客户基础及持续的增长潜力，在工业供应链升级浪潮中占据了显著的先发优势。此次成功登陆港交所，不仅是公司发展的重要里程碑，更将为其后续成长注入强劲动力。作为工业供应链数智化转型的领军者，公司的长期投资价值已然凸显，未来有望在产业升级进程中持续释放增长活力。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Hong Kong’s exports are expected to grow by between 8% and 9% in 2026, according to figures releaased today by the Hong Kong Trade Development Council (HKTDC). The forecast forms part of the HKTDC’s annual Export Outlook report and follows on from the city’s better-than-anticipated 2025 export performance.For 2026, this sustained growth is set to be driven by robust demand for AI-related electronics products. According to the findings of the recently-released HKTDC 4Q25 Export Confidence Index, the majority of exporters (53.2%) see rising demand for AI/new technology-related electronic consumer goods as the factor most likely to boost their 2026 business. This is seen as crucial given that the electronics sector, overall, accounts for more than 70% of Hong Kong’s total export value.Heightened uncertainty giving way to greater clarityThese upbeat figures are remarkable given the high year-on-year comparison base from 2025. This is because many exporters sought to frontload orders in a bid to complete shipments before the imposition of the much-anticipated US tariffs.Detailing the upshot of the tariff-related trade upheavals in particular, Irina Fan, Director of HKTDC Research, said: “While 2025 proved to be a year of heightened uncertainty, 2026 should be a year of greater clarity on global trade. With the Chinese Mainland and the US having come to a trade agreement in November, – some four months after many other nations had struck their own deals with the Trump administration – US tariffs are no longer among Hong Kong exporters' three biggest 2026 concerns.”Fan did, however, acknowledge that uncertainties remain ahead. She said that as US imports from different countries are subject to different levels of tariffs, business leaders around the world will be looking to re-organise their activities to optimise any cost advantages.Outlining what this will mean within the Asia-Pacific region, Fan said: “Chinese Mainland exports to the US will be subject to 20% reciprocal tariff rate until November 2026 [1]. This comparatively low additional tariff puts China-based suppliers, many with more mature and highly productive supply chains, on par with their Southeast Asia counterparts, while giving them a significant advantage over any country subject to a higher tariff rate.”Multi-sector expectation of continued export expansionUnderpinning Hong Kong’s anticipated 2026 export expansion are the findings of the HKTDC Export Confidence Index 4Q25, which was also released today. The two key measures of this long-established quarterly metric –the Current Performance Index (51.4) and the Expectation Index (51.9) – have both stayed above the 50-point watershed level, a clear indication that future export growth is expected.Commenting on the findings of the 4Q25 survey, Kenneth Lee, Head of the HKTDC Research’s Special Project and Business Advisory Section, said: “When it comes to expansion plans over the next two-year period, Asia remains very much the focus. For 42.0% of respondents, the Chinese Mainland was the highest priority market, followed by the rest of Asia (30.3%) and the ASEAN bloc (18.9%). By industry, exporters in almost every sector saw scaling up their activities on the Chinese Mainland as their priority.”Beyond the headline findings of the survey, a more detailed analysis highlights good news for Hong Kong exporters in terms of both individual market prospects and the likely future success of most of the city’s key industry sectors.Positive sentiments for major markets and key industry sectorsIn specific terms, turning to the Market Expectation Sub-Index, the Chinese Mainland (57.2) and the ASEAN bloc (57.0) are still considered to have significant growth potential. Predictably, this was less the case for the US (down 1.4 to 38.0), with the uncertainties in its trade environment continuing to unsettle Hong Kong exporters.Turning to individual industries, a number of sectors have expansionary expectations for the year ahead (i.e. had a relevant index reading of 50 or more). Topping the list is Jewellery (54.8), followed by Electronics (52.4), Timepieces (51.6) and Equipment/Materials (51.1).Despite such overall positive sentiments, the survey also points out the possibility that a number of challenges may lie ahead. Most notably, it cited rising labour and production costs (53.9%), growing logistics challenges (38.8%) and declining overseas orders on account of the general economic slowdown (38.2%) as potential future concerns.[1] On top of Trump 1.0 tariffs of ~20% on averageReferencesHong Kong 2026 Export Outlook: Sustained AI Product Demand Set to Drive 8-9% Growth Over Coming Year:https://research.hktdc.com/en/article/MjE4ODc2Mzk2NwHKTDC Export Confidence Index 4Q25: End-of-Year Figures Indicate Positive Expansion Prospects:https://research.hktdc.com/en/article/MjE4ODYyNTQwNwHKTDC Research website: https://research.hktdc.com/en/ Photo download: https://bit.ly/4oJPrPRHKTDC Director of Research Irina Fan (right) and HKTDC Section Head, Special Project & Business Advisory, Kenneth Lee (left) announced the HKTDC Export Confidence Index for 2025’s fourth quarter at a press conference todayHKTDC Director of Research Irina FanHKTDC Section Head, Special Project & Business Advisory Kenneth LeeMedia enquiriesPlease contact the HKTDC’s Communication and Public Affairs Department:Navin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, December 12, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (“Everest Medicines China”), has entered into two strategic agreements with privately held Hasten Biopharmaceutical Co., Ltd. (“Hasten”). The first is a Commercialization Services Agreement leveraging Everest's existing sales and marketing organization to provide commercialization services for a portfolio of Hasten's mature assets.The second is a License Agreement granting Everest the exclusive license to develop, register and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor, which is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) in Greater China.The two agreements are expected to create significant financial and strategic synergies, enhancing the operational efficiency of Everest’s existing commercial platform and accelerating the build-out of life-cycle and multi-channel commercialization capabilities. At the same time, they establish an attractive strategic footprint for the Company in the cardiovascular disease area. Through this collaboration, Everest will further strengthen its commercial foundation in China, expand market share, and inject core momentum into the long-term growth of its cardiovascular business. The potential approval of Lerodalcibep in Greater China in 2027 is expected to contribute to future revenue growth within Everest's cardiovascular portfolio.Commercialization Synergies to Strengthen Competitiveness Across a Multi-Product PortfolioEverest Medicines China will receive service fees from Hasten calculated by multiplying the net sales of each product for the applicable quarter by the applicable rate, which ranges from 20% to 55%. The proposed maximum annual caps for the transactions contemplated to be paid by Hasten for the three years ending December 31, 2028 are set at RMB 560 million in 2026, RMB 616 million in 2027, and RMB 677 million in 2028.The Commercialization Service Agreement covers six mature, commercially available products across three major therapeutic areas—critical care, cardiovascular disease, and metabolic disorders—including Rocephin(R), Stilamin(R), and Ebrantil(R) in critical care; Edarbi(R) and Blopress(R) in cardiovascular disease; and Basen(R) in metabolic disease. The portfolio is highly synergistic with Everest’s existing commercial infrastructure and strategic focus. Among them, the three core critical care products—Rocephin(R), Stilamin(R), and Ebrantil(R)—play an essential clinical role in the treatment of infectious, gastrointestinal emergency, and cardiovascular emergency conditions. Rocephin(R), for example, is a broad-spectrum, third-generation cephalosporin that has achieved coverage in more than 8,500 hospitals nationwide and holds over 80% market share, maintaining strong and sustained clinical demand in the treatment of complex infections. Notably, these transactions are expected to generate significant synergies for Everest by aligning XERAVA(R) with Hasten’s critical care portfolio — including Rocephin(R) and Stilamin(R) — across complementary geographic footprints, channel access and hospital coverage, while further strengthening the Company’s commercialization capabilities and life-cycle management of innovative medicines.With the addition of this product portfolio, the Company’s commercial presence in key therapeutic areas such as critical care and cardiovascular diseases will be further expanded, creating stronger synergies with its existing commercialization organization and providing more robust support for the scaled development and revenue growth of its commercial platform.Introduction of Lerodalcibep to Expand Strategic Footprint in Cardiovascular DiseasesThe agreement grants Everest the exclusive license to develop, register and commercialize Lerodalcibep in Greater China, together with a royalty-free, exclusive license to use Hasten's trademarks for the product in the territory. Pursuant to the license agreement, Everest Medicines China will make an initial payment of US$29 million (approximately RMB 205 million), and may pay up to US$30 million (RMB 212 million) in potential development and regulatory milestone payments and up to US$280 million (RMB1977 million) in potential sales milestones, in addition to royalties based on the total, aggregate annual net sales.Lerodalcibep, developed by privately-held and U.S.-based company LIB Therapeutics, is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep is a novel, small protein-binding, third-generation PCSK9 inhibitor, and has been developed as a more patient friendly and convenient, once-monthly, single small-volume, subcutaneous injection that will not require refrigeration at home or in travel. These features make Lerodalcibep a unique alternative to approved PCSK9 inhibitors. In large, global phase 3 clinical trials in over 2,500 patients, Lerodalcibep has demonstrated sustained LDL-C reductions of >60% in patients with, or at very-high or high risk of, cardiovascular disease (CVD) and >55% in those with heterozygous familial hypercholesterolemia (FH) who have more severe LDL-C elevations. In addition, the head-to-head LIBerate-VI study, comparing Lerodalcibep with Inclisiran, demonstrated the superiority of Lerodalcibep (p=0.0319). Lerodalcibep is expected to expand treatment options for the millions of patients around the world with CVD, including the 30 million individuals with FH. These LDL-C reductions have been confirmed in a recent phase 3 clinical trial in a Chinese population with, or at very high risk of, CVD including FH.Multiple PCSK9 inhibitors are currently approved and marketed in China, with a combined market size of approximately RMB 3 billion and year-over-year revenue growth of 95% in 2024. The market is expected to further increase to approximately RMB10 billion in 2030, according to a Frost & Sullivan report. Despite an estimated 400 million individuals in China with dyslipidemia, only ~14% receive lipid-lowering treatment, reflecting low penetration and significant unmet medical need. Lerodalcibep has patent exclusivity in China through 2039.Lerodalcibep is currently under regulatory review by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In Greater China, Biologics License Application (BLA) submission is expected in 1H 2026, with the potential for approval in 2027.Everest considers Lerodalcibep an important future growth driver and a key addition to its innovative medicines portfolio. The transaction is viewed as aligned with the Company’s strategy to focus on high-potential therapeutic areas and to expand its late-stage pipeline through business development collaborations, thereby strengthening its overall portfolio.Market commentators note that the two agreements provide both near-term revenue contribution and clear longer-term growth opportunities. By leveraging its established medical, market access, marketing and sales capabilities, Everest is expected to improve the efficiency of its commercial operations and resource utilization, while further demonstrating the scalability and resilience of its commercial platform. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2025年12月12日 - (亚太商讯 via SeaPRwire.com) - 12月11日，海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK）担任配售代理牵头行，协助国泰海通金融控股有限公司（以下简称"国泰海通金控"）成功发行非银金融机构首单上海自贸离岸债，发行规模为5亿元离岸人民币，期限为364天，票面利率为1.8%，由上海清算所登记托管。本次发行是首单以中资券商为信用主体发行的上海自贸离岸债，同时为上海自贸离岸债发行以来单笔最大规模的发行之一。该笔发行遵循发行端、投资端"两头在外"原则，吸引诸多境外投资者在上海清算所开户并踊跃认购，助力上海自贸离岸债投资者体系扩容，推动构建与上海国际金融中心相匹配的离岸金融体系。本次上海自贸离岸债为国泰海通金控更名后首次在国际资本市场亮相，国泰海通金控今年8月获标普授予BBB+长期信用评级（展望"稳定"）后，年内陆续完成可交换债券和上海自贸离岸债的发行，进一步丰富其境外融资工具储备、夯实了独立境外融资能力。本次债券发行亦充分发挥了国泰海通集团内部的协同效应，国泰海通金控与集团总部统筹协调，由国泰君安国际、海通国际、海通银行等联合担任配售代理机构，有力保障债券成功发行。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"A"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球84%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2025年12月11日 - (亚太商讯 via SeaPRwire.com) - 近日，《商业周刊》彭博绿金2026值得关注榜单在上海正式发布。国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK）凭借在绿色金融领域的卓越表现与创新实践，成功入选"绿色金融机构榜单"。国泰君安国际始终将绿色金融作为战略发展的核心驱动力，系统构建了具有行业引领性的可持续发展金融体系。公司不仅将绿色理念全面融入投融资决策与业务运营，更通过创新产品与服务，积极推动低碳经济转型与长期价值共创。凭借在绿色债券、碳资产管理和可持续投资等关键领域的深入实践与突出成效，公司已赢得市场与监管机构的高度认可与持续信任。面向未来，国泰君安国际将进一步发挥专业优势，持续拓展绿色金融产品矩阵，深化绿色金融工具创新与应用，不断延伸绿色金融生态的广度与深度，为经济社会高质量发展注入持久绿色动能。彭博绿金隶属于国际领先的媒体集团Bloomberg彭博，是全球及中国首个全面聚焦绿色经济的媒体平台。近年来，彭博绿金推出多个具有行业影响力的权威榜单，积极引领并推动企业在可持续发展领域的卓越实践。"绿色金融榜单"是彭博绿金首次推出的全新榜单，旨在响应国家绿色金融政策号召，推动金融机构与企业绿色转型，助力实现"双碳"目标。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"A"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球84%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2025年12月11日 - (亚太商讯 via SeaPRwire.com) - 由香港专业财经媒体《信报财经新闻》主办的"上市公司卓越大奖2025"颁奖典礼在香港成功举办。国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK）凭借卓越表现，再度荣获"主板"类别大奖，蝉联此项殊荣。近年来，国泰君安国际持续推动多元化发展战略，坚持稳健经营与风险管控并重，不断深化业务布局、推动创新转型，实现财富管理、企业融资、投资管理等核心业务协同并进，整体经营质效显著提升。展望未来，公司将继续秉持"稳中求进"的发展基调，致力于构建覆盖多元客户群体的全周期综合金融服务平台，推动可持续的高质量增长，为股东创造长期回报。《信报财经新闻》创刊于1973年，是香港首份以财经新闻为主的中文报纸，在业界享有广泛影响力与权威性。"上市公司卓越大奖"评选已连续举办十届，依托《信报》独家研发的EJFQ"信号"系统，依据皮尔托斯基分数、专业分析师推荐频次、股价表现及财务指标四大核心准则筛选入围企业，并由行业领袖、商会代表、专业顾问及评审委员会共同审核，评选出表现卓越的上市公司。该奖项以其公正、专业的评选机制，在资本市场获得高度认可。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"A"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球84%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
SHENZHEN, Dec 11, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms.Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals.The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients.More Information about Y-3 for InjectionThe pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects.The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent.About StrokeAccording to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
5N+ Purity and On-Spec EBC Confirm Lac Knife's Potential as a North American Source of Ultra-High-Performance Graphite ApplicationsOttawa, Ontario--(ACN Newswire via SeaPRwire.com - December 11, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and innovator of next-generation battery technology, is pleased to announce that follow-on purification and elemental analysis of material from its Lac Knife deposit (concentrate Lot ID: GN25073005) achieved 99.9996 wt.% ("5N+") and an Equivalent Boron Concentration ("EBC") of 2.03 ppm, confirming the material is within nuclear-grade specification and meets the technical thresholds required for several high-value advanced materials markets.The test work, conducted using electrothermal purification with no halogen gases (e.g. chlorine) or acids, produced this ultra-pure result in two (2) hours, further validating a chemical-free, environmentally advantageous pathway compared to conventional purification methods. These results directly support Focus's ongoing engineering and scale-up programs funded under Natural Resources Canada's ("NRCan") Global Partnerships Initiative ("GPI"), under which the Company was awarded a non-repayable contribution of up to $14.1 million to accelerate North American capacity for clean, advanced material processing.Subsequent elemental analysis calculated in accordance with ASTM C1233-15: Standard Practice for Determining Equivalent Boron Contents of Nuclear Materials yielded an Equivalent Boron Concentration ("EBC") of 2.03 ppm (Table 1), which falls below the critical 3 ppm threshold often cited for nuclear-grade graphite applications. The calculated EBC value is the most critical test of purity for nuclear industry use.These results suggest that Lac Knife graphite has the potential to serve markets requiring ultra-high-purity large and jumbo flake natural graphite. Achieving both 5N+ purity and a high proportion of large-flake concentrate is uncommon in the natural graphite industry and may provide Focus with opportunities in markets historically reliant on synthetic graphite or otherwise inaccessible to peers. These findings are consistent with peer-reviewed research published in ACS Omega ("Ultrahigh Temperature Purification of Graphite for the Development of a Continuous Process," ACS Omega, 2025), conducted by American Energy Technologies Company ("AETC") and NRCan, which demonstrated that ultrahigh-temperature purification of natural Canadian graphite can produce materials exhibiting purity and crystallinity suitable for advanced applications. Focus's ongoing testwork indicates that residual impurities appear primarily on the surface of the graphite flake—as evidenced by ultra-fine features observed through scanning electron microscopy—suggesting that purification efficiency is strongly influenced by surface cleaning dynamics rather than structural defects within the carbon lattice.Dean Hanisch, Chief Executive Officer of Focus commented, "These results validate Lac Knife as one of the rare unique natural graphite deposits capable of competing in high margin advanced technological markets and as a potential alternative to synthetic materials that are more expensive and have a larger environmental impact. With support from Canada's Federal Government, through Natural Resources Canada's Global Partnerships Initiative, we are now positioned to accelerate our scale-up work and unlock commercial pathways across nuclear energy, defense systems, graphene production, and next-generation electronics."Lac Knife graphite's combination of ultra-high purity and large flake distribution positions it for a range of advanced industrial, clean energy, and high-technology applications.Unlocking Advanced Markets Beyond NuclearBeyond nuclear applications, the ultra-high purity and medium-grain morphology of Lac Knife graphite position the material as a strategic feedstock for several advanced technology markets facing supply shortages, performance bottlenecks, and increasing scrutiny over material purity.Graphene & Few-Layer Graphene (FLG) ProductionIn the graphene sector, precursor quality is the primary determinant of performance. Impurities commonly found in natural graphite—typically 0.5-1 microns in size, or roughly one thousand (1000) times thicker than a graphene layer—are known to disrupt electrical, thermal, and mechanical properties unless fully removed. Lac Knife's 5N+ purity eliminates these defects at the source, allowing the flake to exfoliate cleanly into high-value graphene structures.Peer-reviewed research published in Carbon ("Influence of graphite geography on the yield of mechanically exfoliated few-layer graphene," Carbon, 2023) demonstrates the significance of geological origin in FLG production. In follow-on AETC—Yale University testing based on the methodologies outlined in that study, Lac Knife graphite achieved a record-high few-layer graphene yield of 22% ± 3%, outperforming all other natural samples evaluated and showing exfoliation behavior that synthetic graphite could not replicate.Taken together, these results position Lac Knife as one of the few North American natural flake sources capable of supplying advanced graphene markets, including conductive coatings, EMI-shielding materials, flexible electronics, sensors, and next-generation energy storage systems.Defence: IR Obscuration & Countermeasure SystemsThe defence sector presents another major opportunity. Modern warfare increasingly requires materials capable of obscuring both visible and infrared signatures. Traditional obscurants—such as bronze flakes, titanium dioxide, and red phosphorus—pose toxicity, safety, and performance challenges. High-purity graphite and graphene derived from Lac Knife offer a lightweight, non-toxic, and thermally stable alternative capable of generating rapid-dispersion and longer-lasting obscurant clouds.These materials are applicable to 40 mm muzzle-blast cartridges, airburst obscuration rounds for UAVs and rotorcraft, countermeasure dispenser systems, and naval surface-ship defence platforms. The U.S. Department of War currently procures graphene-based obscurants at approximately US$30,000 per ton, reflecting both strategic importance and limited supply. Lac Knife's purity is essential here, as impurities directly interfere with graphene formation and degrade obscurant performance.Stealth Coatings & Electromagnetic Protection SystemsUltra-high purity graphite also plays a critical role in stealth coatings and electromagnetic protection systems. Engineered systems operating across the 400 MHz to 30 GHz spectrum require materials that deliver highly reproducible electrical conductivity, thermal stability, and particle uniformity.These coatings and composites are used in radar-absorbing structures for stealth UAVs, thermal-vision targeting systems, and a range of low-observable technologies. Because deviations in graphite purity can compromise system reliability or operator safety, defence and shielding markets pay substantial premiums—often up to US$50,000 per ton—for 5N-grade material. Lac Knife's combination of purity, consistency, and grain structure aligns closely with these stringent requirements and allows for further refinement into fine, superfine, ultrafine, or microfine grades without compromising integrity.Critical Infrastructure Hardening (HEMP, IEMI and Geomagnetic Storms)The same purity advantages extend into critical infrastructure protection. As governments and utilities work to harden electrical grids, substations, and 5G networks against high-altitude electromagnetic pulses (HEMP), intentional electromagnetic interference (IEMI), and severe geomagnetic storms, materials must perform reliably across high-frequency ranges and under extreme operating conditions.Graphite-based shielding and coatings designed for these systems rely on predictable, reproducible material behavior—standards that only ultra-high purity graphite can meet. Lac Knife's 5N+ output offers the reliability required for these mission-critical applications.Additional High-Value Markets Enabled by 5N+ PurityIn addition to these strategic sectors, Lac Knife's purity profile and particle characteristics also unlock potential in several high-value industries, including thermal management components for semiconductors and LEDs, high-pressure synthetic diamond production, PEM and SOFC fuel-cell bipolar plates, and laboratory-grade graphite consumables where contamination must be tightly controlled. In each of these markets, ultra-high purity reduces defects, increases stability, and improves overall system performance, enabling natural graphite to compete directly with synthetic alternatives.Next Steps in Technical ValidationFocus is advancing a comprehensive technical qualification program to further define Lac Knife's suitability for nuclear and advanced material markets. Ongoing nuclear graphite testing includes detailed characterization of particle size distribution, compressibility, electrical resistivity, and coefficient of friction—parameters that determine whether a graphite material can perform reliably under the thermal, mechanical, and irradiation stresses present in high-temperature reactor environments. The Company expects to fabricate and evaluate near-net-shape graphite bricks, an essential step toward assessing Lac Knife material in full-scale core component geometries and within ASME Division 5 design criteria.In parallel, Focus is extending its validation program—supported through NRCan's Global Partnerships Initiative ("GPI")—advanced materials markets. Current work programs under consideration include assessing Lac Knife graphite as a precursor for high-yield graphene, nano-wafer substrates, thin-film semiconductors, next-generation electronic components, and aerospace composites, including unmanned aerial systems (UAS). These sectors demand highly reproducible, ultra-high-purity carbon materials traditionally sourced from synthetic graphite. Early results indicate that Lac Knife's 5N+ natural graphite may offer a technically competitive—and potentially more sustainable—North American alternative to synthetic feedstocks across multiple high-value applications.ElementImpurity Limit (mg/kg)EBC FactorEBC CalculationAg0.050.00830.000415Al10.00010.0001B0.1210.12Ca0.360.00020.000072Cd50.31721.586Cl1.50.01340.0201Co0.050.00890.00445Cr0.120.00080.000096Cu0.250.00080.0002Dy0.050.08180.00409Eu0.10.4250.0425Fe0.210.00060.000126Gd0.054.39910.219955K0.60.00080.00048Li0.030.14390.004317Mn0.120.00340.000408Mo0.150.00040.00006Na0.0850.00030.0000255Ni0.180.00110.00198S1.40.00020.00028Si1.460.00010.000146Sm0.050.53360.02668Th0.010.00050.000005Ti0.530.00180.000954U0.050.00050.000025V0.080.00140.000112 Total 2.0277895 Table 1: EBC Calculation, Thermally Purified Lac Knife Lot ID: GN250730005Figure 1: Particle Size Distribution, Thermally Purified Lac Knife Lot ID: GN250730005To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/277711_279dc9a07490cbe0_001full.jpgTap DensityScott VolumeSurface AreaLOI g/ccg/ccm2 /gWt. % C0.60.41.499.9996 Table 2: Data, Thermally Purified Lac Knife Lot ID: GN250730005% TileSize (um)D10105.2D50337.3D90673.8MV368.5 Table 3: Data (2), Thermally Purified Lac Knife Lot ID: GN250730005Qualified PersonDr. Joseph Doninger, Director of Technology and Manufacturing for Focus Graphite, is the Qualified Person ("QP") as defined under National Instrument 43-101 - Standards of Disclosure for Mineral Projects. Dr. Doninger has reviewed and approved the technical information contained in this news release. Dr. Doninger is a chemical engineer and the developer or co-developer of multiple U.S., European, and Canadian patents relating to carbon processing technologies and purification equipment. He has authored or co-authored more than two dozen technical papers and studies on graphite composite anodes, carbon-based materials for electrochemical energy storage systems, and advanced graphite for lithium-ion batteries.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.com.LinkedIn: https://www.linkedin.com/company/focus-graphite/ X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated performance and downstream applicability of ultra-high-purity graphite derived from the Lac Knife project; the potential for 5N+ purification results and nuclear-grade Equivalent Boron Concentration ("EBC") values to be replicated at larger scale; the implications of testwork conducted under Natural Resources Canada's Global Partnerships Initiative ("GPI") and the expected outcomes of related engineering, scale-up, and validation programs; the ability of Lac Knife graphite to meet nuclear, graphene, defense, electromagnetic shielding, thermal management, semiconductor, and other advanced material specifications; the potential commercial pathways associated with supplying high-purity natural graphite as an alternative to synthetic graphite; and the Company's strategy to position itself within North American supply chains for clean energy, advanced manufacturing, aerospace, and critical infrastructure markets.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277711 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
KUALA LUMPUR, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – CBL International Limited (NASDAQ: BANL) (the “Company” or “CBL”), the listing vehicle of the Banle Group (“Banle” or “the Group”) is honored to announce that Dr. Teck Lim Chia, Chairman and Chief Executive Officer of CBL International Limited, has been selected as an Awardee in the Directors of the Year Awards – Listed Companies Executive Directors category, presented by the Hong Kong Institute of Directors (HKIoD).This esteemed accolade follows a comprehensive evaluation by an independent panel of judges comprising senior business leaders, governance experts, and institutional investors. The award recognizes Dr. Chia’s outstanding contributions to corporate governance, exemplary board leadership, and his proven track record in driving sustainable value creation for shareholders and stakeholders.The HKIoD Directors of the Year Awards are among Asia’s most respected honors in corporate governance. Awardees are chosen based on demonstrated excellence in strategic oversight, ethical leadership, transparency, and long-term sustainable performance—all hallmarks of Dr. Chia’s tenure at CBL International. As Chairman and CEO, Dr. Chia has led the Group through a period of transformative growth while embedding governance excellence into the company’s core. Under his stewardship, CBL has strengthened its investor relations framework, enhanced ESG disclosures, deepened stakeholder engagement, and maintained rigorous compliance with international standards throughout its expansion across Asia Pacific, Europe, Central America and Africa.In accepting the award, Dr. Teck Lim Chia said: “I am deeply humbled and grateful to receive this prestigious recognition from the Hong Kong Institute of Directors. This honor belongs not to me alone, but to our entire board, management team, and employees who share a relentless commitment to integrity, innovation, and responsible growth. At CBL, we believe governance is not a box to check — it is the compass that guides every decision. I will continue to lead with purpose, accountability, and vision, always placing the long-term interests of our stakeholders first.”The Board of CBL International expressed its pride in Dr. Chia’s achievement: “Dr. Chia’s leadership has been instrumental in shaping CBL into a globally recognized, governance-forward enterprise. His ability to balance strategic ambition with disciplined oversight exemplifies what modern corporate leadership should be. We congratulate him on this well-deserved honor.”Photo caption: Dr. Teck Lim Chia (right), Chairman and CEO of CBL International Limited, honored at the Directors of the Year Awards – Listed Companies Executive Directors category by the Hong Kong Institute of Directors (HKIoD).Photo caption: The trophy for Directors of the Year Awards – Listed Companies Executive Directors category by the Hong Kong Institute of Directors (HKIoD).About the Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications.For more information about our Company, please visit our website at: https://www.banle-intl.com. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
吉隆坡, 2025年12月11日 - (亚太商讯 via SeaPRwire.com) - 亚太地区领先的船用燃料物流公司万利集团（"万利"或"该集团"）之上市主体CBL International Limited（纳斯达克股票代码：BANL）（以下简称"公司"或"CBL"）宣布，集团主席兼行政总裁谢威廉博士在由香港董事学会（HKIoD）主办的"年度董事大奖"中，荣获"上市公司执行董事"类别大奖。此项殊荣经过由资深商业领袖、公司治理专家及机构投资者组成的独立评审团全面评估后授予。该奖项表彰了谢威廉博士在公司治理方面的卓越贡献、卓越的董事会领导能力，以及其在为股东及持份者创造可持续价值方面的杰出成就。香港董事学会"年度董事大奖"是亚洲最具声望的公司治理荣誉之一。 获奖者基于在策略监督、道德领导、透明度及长期可持续表现方面的卓越表现而获选——这些正是谢威廉博士在CBL International内的核心特质。作为集团主席兼行政总裁，谢博士引领集团经历转型式增长，同时将卓越治理融入公司核心。在他的领导下，CBL加强了投资者关系框架，提升了环境、社会及管治（ESG）披露水平，深化了持份者参与度，并在集团业务拓展至亚太地区、欧洲、中美洲及非洲的过程中，始终保持严格的国际标准合规性。谢威廉博士在领奖时表示："能够获得香港董事学会这一崇高荣誉，我感到谦卑与感激。此项殊荣不仅属于我个人，更属于我们整个董事会、管理团队及全体员工，他们与我一样，对诚信、创新及负责任增长怀有不懈承诺。在CBL，我们深信公司治理绝非简单的合规检查——它是指引每一项决策的指南针。我将继续以目标、问责及远见引领集团发展，始终将持份者的长期利益置于首位。"公司董事会表示："谢威廉博士的领导力对塑造CBL成为全球认可、以治理为先的企业至关重要。他能够在策略雄心与审慎监督之间取得平衡的能力，充分体现了现代企业领导者应有的风范。我们衷心祝贺他获得此项实至名归的荣誉。"图片说明：CBL International Limited 主席兼行政总裁谢威廉博士（右），获颁香港董事学会"年度董事大奖"之"上市公司执行董事"类别殊荣。图片说明：香港董事学会"年度董事大奖"之"上市公司执行董事"奖杯关于万利集团万利集团成立于 2015 年，以CBL International Limited（纳斯达克：BANL）在纳斯达克股票市场上市。我们致力于为客户提供一站式燃油供应服务，被业内称为燃油供应服务商。我们主要通过当地实体供货商为船舶提供燃油加注服务，遍布比利时、中国、香港、印度、日本、韩国、马来西亚、毛里裘斯、巴拿马、菲律宾、新加坡、台湾、泰国、土耳其和越南，共覆盖65个港口。集团积极推动可持续燃料，并已取得ISCC EU和ISCC Plus认证。如欲了解更多信息，请到集团网站https://www.banle-intl.com浏览。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Since 2025, driven by both policy tailwinds and fundamental strengths, the innovative drug sector in the Hong Kong stock market has experienced a valuation recovery. Although it experienced some correction in the second half due to external environmental factors, its overarching growth logic remains intact. Institutional analysis indicates that innovative drugs continue to represent the clearest industry trend within the pharmaceutical sector, with promising development prospects ahead.Among the players, Cloudbreak Pharma (2592.HK), a biotech company focused on ophthalmology, has recently demonstrated strong stock performance. As of December 9, its share price closed at HK$8.24, having accumulated a gain of over 80% in approximately two weeks, and making it a standout "star stock" in the capital markets. This impressive performance is not coincidental but rather the inevitable result of multiple positive catalysts converging, including breakthroughs in its core product pipeline, enhancements to its global intellectual property (IP) layout, and an upgrade of its core management team.Securing Another Victory in Patent Layout, Accelerating Commercialization of Core ProductOn November 27, Cloudbreak Pharma's wholly-owned subsidiary, ADS Therapeutics LLC, successfully secured two core patents in Japan and Europe. Both patents relate to ophthalmic topical compositions and their uses for the core product CBT-009, laying a legal foundation for its global commercialization.As a novel atropine ophthalmic formulation for treating myopia in children and adolescents aged 5 to 19, CBT-009, with its unique non-aqueous formulation design, demonstrates potential advantages over traditional aqueous formulations in terms of drug stability, safety, and patient tolerability, positioning it as a potential best-in-class product. Currently, the product's development is progressing steadily. It received U.S. FDA approval to initiate Phase 3 clinical trial in September 2024. Juvenile animal toxicity studies in China commenced in February 2025, and preparations for Phase 3 clinical trial are actively underway.The grant of these patents in Japan and Europe not only strengthens the global IP portfolio for CBT-009, but will also accelerate its commercialization process. Leveraging patent protection, the Company has the potential to establish partnerships with global pharmaceutical giants to advance the product's production and distribution in key markets like Japan and Europe, accelerating global market penetration. Given the severity of the global adolescent myopia issue, CBT-009 is expected to become a core engine for the Company's future performance growth.Pipeline Progress Across Multiple Fronts; CBT-004 Advances Towards Phase 3Beyond CBT-009, another promising drug candidate from Cloudbreak Pharma, CBT-004, has also reached a significant milestone. As a potential first-in-class drug for vascularized pinguecula, CBT-004 uses Multi-Kinase Inhibitor targeting Vascular Endothelial Growth Factor Receptor (VEGFR) and Platelet-Derived Growth Factor Receptor (PDGFR). According to the Company's latest disclosures, CBT-004 yielded positive results in a Phase 2 clinical trial evaluating its safety and efficacy in treating pinguecula. The Company has begun advancing its Phase 3 clinical development and is scheduled to meet with the United States Food and Drug Administration (the “FDA”) on December 10 (Pacific Standard Time, PST) at an End-of-Phase 2 meeting to establish a regulatory pathway for potential approval.It is understood that there are currently no approved drugs globally specifically for treating vascularized pinguecula. Existing treatment options mostly offer temporary symptomatic relief, leaving significant unmet clinical needs. Should CBT-004 successfully complete development and gain approval, it would become the first targeted therapy, rapidly capturing market share with its unique efficacy advantages. This would create a new revenue stream for the Company while further solidifying its leading position in the field of ophthalmic innovative drugs.Strengthened Executive Team Elevates Commercialization CapabilitiesThe success of innovative drugs relies not only on R&D prowess but also on robust commercialization capabilities to realize their value. On December 1, 2025, Cloudbreak Pharma announced the official appointment of Mr. Michael Rowe as its new Chief Business Officer (CBO), injecting key momentum into the Company's global commercial strategy.Public information shows that Mr. Michael Rowe possesses substantial hands-on commercialization experience across senior management, marketing, sales management, and clinical operations. He is particularly skilled in driving organizational efficiency and achieving breakthroughs in innovative business areas. His industry resources and operational capabilities are expected to bring comprehensive enhancements to the Company.This executive appointment coincides with Cloudbreak Pharma’s core products entering a critical preparatory phase for commercialization. Mr. Michael Rowe's joining will strengthen the Company's business development capabilities in European and American markets, accelerating the construction of its global commercial footprint. Currently, through collaborations with companies such as Grand Pharmaceutical Group and Santen, Cloudbreak Pharma has established a commercialization foundation in Greater China and the Asia-Pacific region (excluding China). With the new CBO onboard, the Company is poised to further expand its global partnership network, optimize commercialization strategies, and provide robust support for the market entry of its multiple core products.With Sustained High Industry Growth, Valuation Re-rating Potential RemainsIn recent years, the global incidence of ophthalmic diseases has continued to rise. Conditions like pterygium and adolescent myopia affect hundreds of millions of patients, while the supply of innovative drugs in related treatment areas remains severely inadequate, indicating a vast unmet market need. Concurrently, governments worldwide are increasing support for pharmaceutical innovation, providing a favorable policy environment for high-quality innovative drug companies. Within the Hong Kong stock market, the innovative drug sector is experiencing a favorable trend of valuation re-rating. Companies with solid R&D pipelines, clear commercialization pathways, and core competitiveness are seeing gradually rising valuation expectations.As an innovative drug company dedicated to ophthalmology, Cloudbreak Pharma has built a rich pipeline covering 8 drug candidates targeting major diseases in both the anterior and posterior segments of the eye, forming a diversified product matrix. With steady progress in R&D and an increasingly refined global commercialization strategy, the Company already exhibits scarce growth attributes. The recent short-term surge in its stock price, catalyzed by multiple positive factors, is merely the beginning of value release. As these favorable initiatives are further implemented and pipeline value continues to be realized, Cloudbreak Pharma is poised to achieve dual enhancement in both performance and valuation. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
